ResearchSat
Provides small satellite and sub-orbital platforms for microgravity research in life sciences and advanced materials.
Website: https://researchsat.space/
Cover Block
Publicly reported
| Field | Value |
|---|---|
| Name | ResearchSat |
| Tagline | Provides small satellite and sub-orbital platforms for microgravity research in life sciences and advanced materials. |
| Headquarters | Adelaide, Australia |
| Founded | 2018 |
| Stage | Pre-Seed |
| Business Model | B2B |
| Industry | Deeptech |
| Technology | Space |
| Geography | Oceania |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding Label | Unknown |
| Total Disclosed | $117,000 according to a third-party database [Caplight] |
Links
- Website: https://researchsat.space/
- LinkedIn: https://au.linkedin.com/company/researchsat
Summary and Signal
PUBLIC. ResearchSat builds small satellite and sub-orbital platforms for microgravity research, and it merits investor attention because it is trying to turn space-based life-science experimentation from a bespoke orbital exercise into a lower-cost, sponsor-led workflow with early evidence of real missions, a named customer collaboration, and a new state-backed digital-twin project [ResearchSat company page]; [SASIC, March 2024]; [Lot Fourteen, May 2023]. The company was founded in Adelaide in 2018 by RaviTeja Duggineni and Jibin Jeffrey Dhanaraj, and public reporting suggests it spent roughly its first three years bootstrapping before landing its first client, which matters more here than in software because hardware and mission execution tend to expose weak teams early [InDaily, June 2023]; [SASIC, March 2024].
The product is best understood as an end-to-end microgravity research service: payload design, launch access, mission operations, and data return for life-science and pharmaceutical experiments, with the wedge resting on smaller, cost-conscious platforms rather than large orbital infrastructure [Linknovate Stories]; [ResearchSat]; [DigiTimes, October 2025]. That positioning has some public market signal behind it. ResearchSat has cited applications across pharmaceuticals, semiconductors, agriculture, and space biology, while DigiTimes reported mission participation pricing of about NT$75,000 per 0.5 ml sample for Taiwanese researchers, a figure that at least points to an effort to standardize access and lower experimental entry costs [DigiTimes, October 2025].
Execution, at this stage, is more tangible than capitalization. Public sources point to an inaugural sub-orbital mission tied to Numedico Sciences, a 2023 ADI-Alpha CubeSat launch from Esrange Space Centre in Sweden, and a 2026 project with AltData and AICRAFT supported through South Australia's Space Collaboration and Innovation Fund [Lot Fourteen, May 2023]; [SASIC, March 2024]; [AltData, February 2026]. The founders' backgrounds fit the problem set: Duggineni is identified in company and third-party materials as an aerospace engineer educated at the University of Adelaide and the founder and CEO, while Dhanaraj is identified as CTO and the technical lead on satellite and payload systems [ResearchSat careers]; [StudyAdelaide]; [UniSA Innovation & Collaboration Centre, 2019]; [SASIC, March 2024].
Funding remains the least resolved part of the story. No confirmed institutional equity round appears in the available public record, although third-party databases and grant-related coverage indicate limited external funding, including a reported A$150,000 South Australian grant for the AltData and AICRAFT project and an unverified database entry of $117,000 total funding [AltData, February 2026]; [Caplight]. On the public evidence, this still looks like a B2B, pre-seed deeptech company selling mission access and research services, with the next 12 to 18 months likely hinging on whether it can convert grant-backed technical credibility and cross-border interest in Taiwan into repeat commercial programs and clearer proof that its digital-twin layer improves the value of microgravity experiments rather than simply accompanying them [DigiTimes, October 2025]; [LinkedIn, February 2026].
Data Accuracy Score: YELLOW. This section relies on a mix of independent reporting, state ecosystem sources, and company-published materials; the core company, mission, and team facts are reasonably supported, while funding detail and some product-expansion claims remain only partially corroborated.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Pre-Seed |
| Business Model | B2B |
| Industry / Vertical | Deeptech |
| Technology Type | Space |
| Geography | Oceania |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
Company Overview
PUBLIC
ResearchSat presents as a narrowly focused space-biotech company rather than a broad platform claim. The public record ties the business to Adelaide, Australia, shows a 2018 founding date, and describes a company built around small satellite and sub-orbital platforms for microgravity research in life sciences and advanced materials [researchsat.space]; [Gust].
The founding team publicly identified across company and startup-profile materials consists of RaviTeja Duggineni and Jibin Jeffrey Dhanaraj [researchsat.space]; [Gust]. Public materials also place the company within Adelaide's local innovation infrastructure, with activity associated with the University of South Australia's Innovation and Collaboration Centre and the Lot Fourteen precinct, although those references speak more to operating base than to legal form [icc.adelaide.edu.au, Unknown]; [researchsat.space].
From the chronology available on the company site, the business appears to have moved from early payload work into live mission activity over 2023. ResearchSat's public website references the ADI-Beta mission, and the company site also positions CubeSat payloads and microgravity experimentation as the core operating pathway [researchsat.space]. Separate startup-directory profiles are consistent on the company's identity and Adelaide base, but do not add verified round, investor, or legal-entity detail beyond the company name in circulation [F6S]; [Gust].
One source, partially checked -- Confirmed in part by the company website and startup-profile directories, with several core facts supported primarily by company-controlled sources.
The Product and the Stack
MIXED The product story is clearest when kept at the level the public record actually supports: ResearchSat is building access to microgravity experiments through small satellite and sub-orbital platforms aimed at life-science and advanced-materials use cases [researchsat.space]; [SASIC, March 2024]. Company materials describe a staged pathway that starts with space-ready payloads and extends to nanosatellite missions and space bioreactors, with experiments spanning bacteria, fungi, biologics, drug delivery, and pharmaceutical formulation [researchsat.space/company/]; [researchsat.space]. Third-party coverage adds that the company presents itself as an end-to-end operator, handling payload design, launch logistics, and data return for research customers [Linknovate Stories].
The technical proof points in public are early but tangible. ResearchSat’s site references the ADI-Beta mission carrying microorganisms to about 300 km altitude, while SASIC reported that the ADI-Alpha CubeSat launched from Esrange Space Centre in Sweden on November 23, 2023 to study microbiological and chemical behavior in microgravity [researchsat.space]; [SASIC, March 2024]. InDaily also reported a 2022 payload effort with RMIT University that reached roughly 260 km, which suggests the company has worked across both sub-orbital and orbital-adjacent research formats rather than a single demonstration path [InDaily, June 2023].
The newer layer is software-assisted biology rather than launch hardware alone. ResearchSat said in a February 2026 LinkedIn announcement that it is building Australia’s first microgravity digital-twin platform for pharmaceutical research, and SASIC described the associated project with AltData and AICRAFT as combining real microgravity experiments with AI to model biological systems [LinkedIn, February 2026]; [SASIC, March 2024]. That broadens the proposition from mission brokerage to decision-support for pharma R&D, although the public evidence does not yet show a verified product demo, published validation data, or a disclosed technical stack, and there are no usable job-posting details here to support stack inferences.
One source, partially checked -- Product scope is supported by company materials and partially corroborated by SASIC and InDaily, but several capability claims remain company-described rather than independently validated.
The Market They Are Entering
Market context
PUBLIC Access to microgravity research is drawing more attention because drug developers, university labs, and national space programs are looking for cheaper ways to test biological and materials behavior off Earth, but the public record here is still stronger on demand signals than on market size [Lot Fourteen, May 2023] [DigiTimes, October 2025]. For ResearchSat, the relevant market is not a neatly published category with a single accepted TAM. It sits at the intersection of commercial space services, contract research for life sciences, and early-stage in-space biotech tooling, and none of the supplied sources provide a third-party TAM, SAM, or SOM specific to microgravity research platforms.
What is visible is the shape of demand. ResearchSat has publicly positioned its offering around lower-cost access to microgravity through small satellites, sub-orbital missions, and space bioreactors, with use cases in pharmaceutical formulation, biologics, bacteria, fungi, and drug delivery [researchsat.space] [SASIC, March 2024]. That framing matters because it shifts the addressable budget from traditional orbital science programs alone toward smaller experimental budgets inside pharma, biotech, and academic research groups. A reported offer price of about NT$75,000 per 0.5 ml sample for Taiwanese researchers suggests the company is trying to productize access at the experiment level rather than sell only large bespoke missions [DigiTimes, October 2025].
The closest public proxy for TAM is therefore an analogous market lens rather than a clean sector total. ResearchSat appears to be pursuing a narrow service layer inside a broader R&D spend pool: preclinical and formulation-stage experiments that may benefit from microgravity conditions, plus space-biology work funded by universities and government-backed programs [Lot Fourteen, May 2023] [SASIC, March 2024]. Without a cited third-party market report, it is more accurate to describe the near-term SAM as funded microgravity experiments in life sciences and advanced materials, especially in Australia and Taiwan, than to force an unsupported dollar figure.
| Cited market signal | What it suggests | Source |
|---|---|---|
| NT$75,000 per 0.5 ml sample mission participation | Experiment-level pricing may widen access beyond national-lab scale programs | [DigiTimes, October 2025] |
| Bootstrapped for three years before first client | Early demand may be real but adoption cycles are long | [InDaily, June 2023] |
| Numedico funded inaugural sub-orbital mission | Pharma-linked buyers will fund application-specific missions when a direct research question is clear | [Lot Fourteen, May 2023] |
| Taiwan collaboration plans with TASA and researchers | Government-linked international channels may help aggregate demand | [DigiTimes, October 2025] |
The practical takeaway is that demand looks episodic but monetizable. Buyers appear willing to pay for defined experiments, yet the evidence still points to a project market rather than a scaled recurring platform market [Lot Fourteen, May 2023] [DigiTimes, October 2025].
Demand drivers and adjacent markets
PUBLIC The most credible tailwind in the source set is cost compression. ResearchSat and third-party coverage both describe a lower-cost route into microgravity research, and that is likely the central commercial driver because conventional orbital research remains capital intensive and operationally complex [SASIC, March 2024] [DigiTimes, October 2025]. If a sponsor can test a formulation, microorganism, or biological pathway through a smaller payload before committing to a larger orbital program, the decision framework starts to look more like staged R&D procurement than frontier space science [researchsat.space] [Linknovate Stories].
A second tailwind is buyer diversification. The sources do not limit demand to pharmaceutical companies. They also point to universities, researchers, semiconductor-related experimentation, agriculture, and space biology, which broadens the set of adjacent budgets that might support paid missions [DigiTimes, October 2025] [Lot Fourteen, May 2023]. That said, broad applicability is not the same thing as near-term revenue density. The public evidence is strongest in life sciences, especially drug-delivery and formulation work, because Numedico Sciences funded the inaugural sub-orbital mission for alternative drug-delivery research [Lot Fourteen, May 2023].
The adjacent and substitute markets are clearer than the core market sizing. On one side sit terrestrial substitutes: conventional lab simulation, computational biology, and preclinical testing environments that compete for the same R&D budget. On the other side sit adjacent markets such as contract research, payload integration, CubeSat-enabled research services, and digital-twin software tied to biological systems in microgravity [researchsat.space] [LinkedIn, February 2026]. ResearchSat's February 2026 announcement around a microgravity digital-twin platform is relevant because it suggests an attempt to extend beyond one-off flight services into software-supported interpretation, although that claim remains company-led and early [LinkedIn, February 2026].
The regulatory and macro picture is supportive, though still programmatic. In Australia, support from the South Australian Space Industry Centre and activity around Lot Fourteen indicate a policy environment that wants more domestic space capability and translational research outcomes [SASIC, March 2024] [Lot Fourteen, May 2023]. In Taiwan, the reported collaboration path with TASA suggests that national agencies may serve as market shapers as much as end customers [DigiTimes, October 2025]. The main macro constraint is that this remains a procurement-heavy category where mission cadence, research grants, export controls, launch access, and cross-border scientific partnerships can all affect timing more than raw interest levels.
One source, partially checked -- Based primarily on named-publication reporting from DigiTimes, InDaily, Lot Fourteen, and SASIC, with some market framing inferred from company materials because no third-party TAM source was provided.
The Competitive Field
MIXED ResearchSat sits in a narrow part of the space-biology stack, between large orbital research infrastructure on one side and terrestrial lab substitutes on the other, with its public positioning centered on smaller, lower-cost microgravity access rather than full-service station-scale capacity [SASIC, March 2024] [DigiTimes, October 2025].
The competitive map is easier to define by substitute category than by a clean list of venture peers, because the source set does not name direct startup competitors. At the top end sit established orbital research environments such as the International Space Station, which ResearchSat itself references through payload-related activity and prize marketing, and which function as the benchmark for credibility, flight heritage, and researcher familiarity [LinkedIn] [ResearchSat]. Those platforms are not direct one-for-one competitors on product form, but they are the incumbent option for investigators who need proven microgravity access, institutional validation, or broad mission support.
A second layer is made up of adjacent providers and research partners that can absorb pieces of the workflow without replicating ResearchSat's full proposition. RMIT University appears in public reporting as a mission partner on an earlier payload, which points to a model where universities, launch intermediaries, and payload specialists can collectively serve the customer need even if no single party looks identical to ResearchSat [InDaily, June 2023]. Up&Up Space, acquired by ResearchSat's co-founders according to InDaily, is better read as enabling infrastructure than as a continuing rival, but the episode underscores how fragmented the market remains and how much capability is still assembled rather than vertically owned [InDaily, June 2023].
Where ResearchSat appears to have an edge today is not scale, it is packaging. Public materials consistently describe an end-to-end offer, from payload design through launch logistics and data return, aimed at life-science and pharmaceutical use cases that are typically too specialized for generic small-satellite vendors and too budget-constrained for large orbital programs [Linknovate Stories] [ResearchSat company page]. The Taiwan pricing signal, approximately NT$75,000 per 0.5 ml sample, reinforces that the company is trying to compete on accessibility and experiment-sized entry points rather than on a large installed platform base [DigiTimes, October 2025]. That edge is useful, but it is also perishable: cost-led differentiation tends to hold only while mission execution stays reliable and while larger providers do not move downmarket with sponsored research programs or standardized payload offerings.
The main exposure is that ResearchSat does not appear, from public evidence, to control a dominant distribution channel, a proprietary launch network, or a deeply cited data moat. Its current position depends on stitching together platform engineering, mission partnerships, and customer-specific programs, with examples including Numedico Sciences, RMIT collaboration, and the South Australian digital-twin project with AltData and AICRAFT [Lot Fourteen, May 2023] [InDaily, June 2023] [AltData, February 2026]. If a better-capitalized microgravity-services company, a national space agency program, or a university-led consortium offers a more validated path for regulated pharma research, ResearchSat could be pushed toward lower-value integration work rather than owning the customer relationship end to end.
The most plausible 18-month scenario is a bifurcation between platform owners and workflow specialists. Winner if execution on pharma-grade data and digital-twin tooling improves: ResearchSat, because the company is already publicly tying microgravity experiments to pharmaceutical decision support rather than selling launch access alone [LinkedIn, February 2026] [SASIC, March 2024]. Loser if customers continue to prefer only the most validated flight environments for early commercial space-biology work: smaller independent mission brokers such as ResearchSat itself, because the public record does not yet show a broad installed base, repeated large enterprise accounts, or a financing profile that would let it outrun incumbent infrastructure providers [InDaily, June 2023] [Lot Fourteen, May 2023].
One source, partially checked -- Competitive positioning is supported by public company materials and third-party reporting, but the source set does not name direct startup competitors or provide independently corroborated market-share evidence.
Opportunity
PUBLIC
If ResearchSat executes, the prize is not a niche launch-services business but a position as a lower-cost research infrastructure layer for pharmaceutical and life-science experiments that need real microgravity data before sponsors commit to larger orbital programs [ResearchSat] [DigiTimes, October 2025].
The headline opportunity is straightforward: become the default early-stage microgravity R&D pathway for drug developers, academic labs, and biotech teams that cannot justify the cost, complexity, or lead times of traditional space-station style access. That outcome is still early, but it is not purely aspirational in the public record. ResearchSat has already framed its offering as a staged pathway from payload design through mission execution and data return [ResearchSat] [Linknovate Stories]. It also has at least some evidence of paid market demand, with InDaily reporting that the company was bootstrapped for three years before securing its first client, and Lot Fourteen reporting that Numedico Sciences funded its inaugural sub-orbital mission for alternative drug-delivery research [InDaily, June 2023] [Lot Fourteen, May 2023].
That matters because the commercial wedge here is narrower, and therefore more credible, than trying to own all of in-space manufacturing or all of orbital biotech. The company appears to be starting with sponsored experiments and smaller research payloads, then layering in repeatable platforms such as CubeSat payloads, space bioreactors, and digital-twin tooling for pharmaceutical research [ResearchSat] [SASIC, March 2024] [LinkedIn, February 2026]. If customers value decision-grade microgravity data rather than bespoke mission engineering alone, ResearchSat could sit in the budget line between terrestrial preclinical work and much larger orbital programs [ResearchSat] [DigiTimes, October 2025].
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Pharma screening rail | ResearchSat becomes a repeat supplier of microgravity experiment campaigns for drug-delivery, formulation, and biologics teams, with sponsors using sub-orbital and orbital tests as a standard validation step before larger programs | A visible customer case converts into repeat pharma work, similar to the Numedico-funded inaugural mission [Lot Fourteen, May 2023] | The company already positions around pharmaceutical research, drug delivery, and biologics, and has shown one named pharma collaboration [ResearchSat company page] [Lot Fourteen, May 2023] |
| Asia-Pacific research gateway | ResearchSat builds a regional access point for universities and national research agencies that want smaller-ticket participation in space biotech missions | Taiwan collaboration activity matures into a repeat cross-border program, supported by the reported sample-pricing model and work with Taiwanese researchers [DigiTimes, October 2025] | DigiTimes reported planned collaboration with the Taiwan Space Agency and mission participation at about NT$75,000 per 0.5 ml sample, which suggests a productized entry point rather than a fully bespoke sale [DigiTimes, October 2025] |
| Microgravity data platform | ResearchSat moves from running missions to owning a proprietary dataset and digital-twin layer for gravity-dependent biological behavior, making each experiment more useful than the last | The South Australian Space Collaboration and Innovation Fund backed project with AltData and AICRAFT produces a working digital-twin workflow tied to real experiments [AltData, February 2026] [SASIC, March 2024] | Public materials already connect real microgravity experiments with AI-enabled digital twins for pharmaceutical research, which is one of the few routes from services revenue to software-like value capture [LinkedIn, February 2026] [AltData, February 2026] |
What compounding could look like is a data-and-workflow flywheel rather than a classic consumer network effect. One sponsored mission produces experimental data, operating know-how, payload validation history, and customer credibility. The next sale should become easier if the company can point to prior sub-orbital and CubeSat missions, named collaborations, and a cleaner operational path from sample prep to returned data [Lot Fourteen, May 2023] [SASIC, March 2024] [ResearchSat].
There is an early hint of that loop in the public record. ResearchSat has moved from a bootstrapped period into a first client engagement, a named CubeSat launch, and then a publicly announced digital-twin project with external collaborators [InDaily, June 2023] [SASIC, March 2024] [AltData, February 2026]. If that sequence continues, the company could improve economics in two ways: more standardized mission architectures on the hardware side, and more reusable biological insight on the software side. The second piece matters most, because proprietary microgravity datasets in formulation, microbes, or biologics would be harder to substitute than launch coordination alone [ResearchSat] [LinkedIn, February 2026].
The size of the win is difficult to anchor precisely from the available public evidence because no confirmed market-sizing source or direct public comparable is provided in the research set. A reasonable upside frame is therefore strategic rather than formulaic: if the microgravity data platform scenario plays out, ResearchSat could become an acquisition target for a larger life-sciences tools company, space infrastructure provider, or pharmaceutical R&D platform seeking differentiated in-space experimentation capability and proprietary biological data, particularly if the Taiwan channel and digital-twin work turn into repeat programs [DigiTimes, October 2025] [AltData, February 2026]. That is a scenario, not a forecast. On the evidence available publicly, the company has at least the outlines of a venture-scale path because it is trying to convert one-off missions into repeatable infrastructure, and repeatable infrastructure into defensible research data.
One source, partially checked -- Based primarily on named public reporting from InDaily, Lot Fourteen, DigiTimes, SASIC, and company-controlled materials, with several core product claims still resting on company sources.
Sources
Publicly reported
[Caplight] ResearchSat | Caplight | https://www.caplight.com/company/researchsat
[DigiTimes, October 2025] Taiwan Space Agency (TASA) to collaborate with Australia's ResearchSat on space biotech | https://www.digitimes.com/news/a20251014PR205/taiwan.html?chid=9
[F6S] ResearchSat | https://www.f6s.com/company/researchsat
[Gust] ResearchSat | Adelaide, South Australia, Australia Startup | https://gust.com/companies/researchsat
[icc.adelaide.edu.au] ResearchSat - Innovation & Collaboration Centre - Adelaide University | https://icc.adelaide.edu.au/about/icc-startups-and-residents/researchsat/
[InDaily, June 2023] Local space company to hit new heights | https://www.indailysa.com.au/news/business/2023/06/27/local-space-company-to-hit-new-heights
[LinkedIn, February 2026] ResearchSat LinkedIn announcement, February 2026 | https://www.linkedin.com/posts/researchsat_microgravity-digital-twins-adv-drug-activity-7429439475988045826-EECO
[LinkedIn] ResearchSat | https://au.linkedin.com/company/researchsat
[Lot Fourteen, May 2023] Space medtech start-up hit major milestone | https://lotfourteen.com.au/news/space-medtech-startup-takes-clinical-research-to-new-heights-to-improve-human-health-on-earthand-beyond/
[ResearchSat] ResearchSat | https://researchsat.space/
[ResearchSat company page] Company , About ResearchSat | Space Biology Research | ResearchSat | https://researchsat.space/company/
[ResearchSat careers] ResearchSat careers | https://researchsat.space/careers/
[SASIC, March 2024] Local start-up reaches new heights for biomedical space research | https://sasic.sa.gov.au/news/local-start-up-reaches-new-heights-for-biomedical-space-research/
[StudyAdelaide] RaviTeja Duggineni | StudyAdelaide | https://studyadelaide.com/why-adelaide/our-alumni/raviteja-duggineni
[UniSA Innovation & Collaboration Centre, 2019] ResearchSat | Innovation & Collaboration Centre | https://icc.adelaide.edu.au/about/icc-startups-and-residents/researchsat/
[AltData, February 2026] South Australian Space Collaboration and Innovation Fund Round 3 recipients announced | https://altdata.com.au/
Articles about ResearchSat
- ResearchSat's Nanosatellites Aim to Lower the Cost of Space Biology — Adelaide startup uses small satellites and a digital twin platform to sell microgravity research to pharmaceutical labs.